New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Cullinan Therapeutics Partner Taiho Oncology Completes NDA Submission To FDA For Zipalertinib In Combination With Platinum-Based Chemotherapy For Treatment Of NSCLC Harboring EGFR Ex20ins Mutations
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44
Cullinan Therapeutics: Q3 Earnings Snapshot
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Cullinan Therapeutics Q3 EPS $(0.74) Beats $(0.84) Estimate
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Reported Sunday, Cullinan Therapeutics Reports Velinotamig Achieved Clinically Meaningful Disease Activity Improvement In 8 Of 9 Evaluable Refractory Lupus Patients, With Four Complete Renal Responses, In Data Presented At ACR Convergence 2026
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Learn Why The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following Trial Clearance
Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?
Cullinan Therapeutics (CGEM) Stock May Be Fully Priced Following Trial Progress
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Cullinan Therapeutics Gets FDA And Australian Therapeutic Goods Administration Clearance To Initiate Its Global Phase 1b/2a Clinical Trial In Adults With Relapsing And Refractory ITP And Warm Autoimmune Hemolytic Anemia
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
Taiho Oncology and Cullinan Therapeutics Say Data From Cohort C Of Phase 2 REZILIENT2 Trial Of Zipalertinib For Locally Advanced Or Metastatic Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Or Uncommon EGFR Mutations and Active CNS Metastases Shows Intracranial Objective Response Rate Of 30.2% In 43 Evaluable Patients
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.